Results 201 to 210 of about 31,440 (256)

Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists. [PDF]

Life (Basel)
Tanasescu MD, Rosu AM, Minca A, Grigorie MM, Timofte D, Ionescu D.   +5 more
europepmc   +1 more source

GLP-1 receptor agonists and functional gastrointestinal obstruction: mechanistic rationale, emerging evidence, and clinical implications. [PDF]

Ann Med Surg (Lond)
Riaz L, Ajmal A, Siddiquei H, Memon U, Jaber Amin JH.   +4 more
europepmc   +1 more source

GLP-1 Receptor Agonists and Blood Pressure: A State-of-the-Art Review of Mechanisms, Evidence, and Clinical Implications. [PDF]

Am J Hypertens
Moiz A, Zolotarova T, Filion KB, Eisenberg MJ.   +3 more
europepmc   +1 more source

Characterising Continuous Glucose Monitoring Metrics Across Normoglycaemia, Prediabetes and Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Simon L. Cichosz, Kristine Færch, Morten H. Jensen   +2 more
wiley   +1 more source

GLP-1 receptor agonists in patients with cancer are associated with reduced all-cause mortality and hospitalization.

J Clin Endocrinol Metab
Mahadevan A, Vosooghi A, Arora JS, Kumar RS, Singh G, Tsai KK, Quandt Z.   +6 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

Diabetes, Obesity and Metabolism, EarlyView.
Juan Manuel Arteaga‐Diaz, Jose Luis Torres‐Grajales, Leobardo Sauque‐Reyna, Carlos Salamanca‐Carrillo, Luis Anguiano‐Medrano   +4 more
wiley   +1 more source

Increasing Postpartum Use of GLP-1 Receptor Agonists.

JAMA
Bliddal M, Nohmie G, Damkier P, Pottegård A.   +3 more
europepmc   +1 more source

GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy.

JAMA Netw Open
Choi T, Al-Aly Z, Xie Y.
europepmc   +1 more source